Lovastatin

Catalog No.S2061 Synonyms: MK-803

Lovastatin Chemical Structure

Molecular Weight(MW): 404.54

Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM in a cell-free assay, used for lowering cholesterol (hypolipidemic agent).

Size Price Stock Quantity  
In DMSO USD 90 In stock
USD 70 In stock
USD 170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • To evaluate the role of cell cycle progression in androgen induced DSB formation, LAPC4 cells were either treated with solvent control or 50 μM lovastatin for 36 h prior to stimulation with 100 nM DHT for 6 h. Note that androgen induced γH2A.X foci formation was not different between control and lovastatin pre-treated cells.

    Clin Cancer Res, 2016. doi:10.1158/1078-0432.CCR-15-1147.. Lovastatin purchased from Selleck.

Purity & Quality Control

Choose Selective HMG-CoA Reductase Inhibitors

Biological Activity

Description Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM in a cell-free assay, used for lowering cholesterol (hypolipidemic agent).
Targets
HMG-CoA reductase [1]
(Cell-free assay)
3.4 nM
In vitro

Lovastatin inhibits LPS- and cytokine-mediated production of NO and expression of iNOS in rat primary astrocytes. Lovastatin inhibits LPS-induced expression of TNF-alpha, IL-1beta, and IL-6 in rat primary astrocytes, microglia, and macrophages. [1] Lovastatin results in over 95% inhibition of DNA synthesis as measured by incorporation of [3H]thymidine into DNA. Lovastatin synchronizes cells in the G1 and not in the G0 phase of the cell cycle. Lovastatin has a similar growth-inhibitory activity against ras-dependent as well as ras-independent cell lines. [2] Lovastatin produces a profound reduction of apolipoprotein-B-containing lipoproteins, especially LDL cholesterol and, to a lesser extent, plasma triglyc- erides, and a small increase in HDL cholesterol. [3] Lovastatin arrests cells by inhibiting the proteasome, which results in the accumulation of p21 and p27, leading to G1 arrest. Lovastatin is an inhibitor of hydroxymethyl glutaryl (HMG)-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Lovastatin can be used to arrest cultured cells in the G1 phase of the cell cycle, resulting in the stabilization of the cyclin-dependent kinase inhibitors (CKIs) p21 and p27. [4] Lovastatin (2-10 mM) arrests cells in G1 and also prolonged--or arrested a minor fraction of cells in--the G2 phase of the cell cycle in human bladder carcinoma T24 cell line expressing activated p21ras. Lovastatin (50 mM) is cytotoxic in human bladder carcinoma T24 cell line expressing activated p21ras. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEP G2 cells Mo\xSpVv[3Srb36gZZN{[Xl? NYjIeFlkUW6qaXLpeIlwdiCxZjDj[YxtfWyjcjDIUWcuS2:DIILl[JVkfGG|ZTDpckBkfWy2dYLld{Bw\iCqZYDheIlkKGOnbHzzJEhJTVBiR{KsJIEhcHWvYX6gbIVx[XSxbXGgZ4VtdCCuaX7lLUwhUUN3ME21[U0xPSEQvF2= MmPiNlE2OzJzMx?=
HES 9 cell line NVLpfGhJTnWwY4Tpc44h[XO|YYm= MmfGR49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IFjNS{1Ed0FicnXkeYN1[XOnIHL5JFUxLSC5YYOg[IV1\XKvaX7l[EBqdiCKRWOgPUBk\WyuIHzpcoUtKEmFNUC9NE4xOTNizszN MV2xOVI4Pzlz
HEP G2 cells MWPGeY5kfGmxbjDhd5NigQ>? MVnU[ZN1\WRiZn;yJIlvcGmkaYTpc44hd2ZiY3jvcIV{fGW{b3ygZolwe3mwdHjld4l{KGmwIFjFVEBIOiClZXzsd{whUUN3ME2wMlAzQSEQvF2= MVi3PVMzPTVz
human SW480 cells NYf6R3pNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUjpSWFQQTZiaB?= M4\C[mdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNYPDhyIHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFNiYYPzZZktKEmFNUC9O{4yKM7:TR?= NHz0ZlkyPzR5Mkm2Ni=>
human HepG2 cells MlvZSpVv[3Srb36gZZN{[Xl? NYLx[lVNPiCq M2S3TGxqeGmmIHzve4VzcW6pIHHjeIl3cXS7IHnuJIh2dWGwIFjldGczKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIH;s[YlkKGGlaXSg[Yxq[2m2ZXSgcIlxcWRiYXPjeY12dGG2aX;uJIFnfGW{IE[gbJJ{KGK7IH;pcE1z\WRiTzDzeIFqdmmwZzDt[ZRpd2RuIFnDOVA:QC5|IN88US=> NETFXIgzPjF4OUGyOS=>
human A549 cells MnTNR5l1d3SxeHnjxsBie3OjeR?= MWW3NkBp M2W1ZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xNU41KM7:TR?= NV7heog4OjN3N{C1OFI>
human HS68 cells Mn;qR5l1d3SxeHnjxsBie3OjeR?= MnezO|IhcA>? M4\uWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhUPjhiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yN{4zKM7:TR?= M{TNd|I{PTdyNUSy
mouse MEF cells NYnBWJhPS3m2b4TvfIlkyqCjc4PhfS=> NHKze2U4OiCq M{nWZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJG1GTiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUO1JO69VQ>? M4XUd|I{PTdyNUSy
human HT29 cells MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV:5OkBp MUTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIWFI6KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHMh[XO|YYmsJGlEPTB;NE[uPEDPxE1? MofsNVc1PzJ7NkK=
human SW480 cells MXfGeY5kfGmxbjDhd5NigQ>? M{PQUlIxKM7:TR?= NF\KbI5KdmirYnn0bY9vKG:oIF\CV{1{fGmvdXzheIVlKGmwY4LlZZNmKGmwIFHreEBxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gV3c1QDBiY3XscJMh[XRiMkCgeW0h[nliaX3teY5w[myxdDDhcoFtgXOrcx?= M3HPZlE4PDd{OU[y
human RPMI8226 cells Moq1RZBweHSxc3nzJIF{e2G7 M1raPFIxKM7:TR?= MorYOFghcA>? MlrjTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCUUF3JPFIzPiClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDjZZNx[XOnLUOgZ4xm[X[jZ3WgZZQhOjBidV2gbY5kfWKjdHXkJIZweiB2ODDodpMh[nliaX3teY5w[myxdDDt[ZRpd2R? NEPq[GszPTl|NU[0Ny=>
human MDA-MB-468 cells NHG2UWZHfW6ldHnvckBie3OjeR?= MXe0PEBp M13RRXRwfGGuIHfyc5d1cCCrbnjpZol1cW:wIH;mJHBTNCCHUjygTGVTOi2wZXfheIl3\SCqdX3hckBOTEFvTVKtOFY5KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDXV3QuOSCjc4PhfS=> NEjQbpgzPDV3NkWwOC=>
human MDA-MB-361 cells  M2W4cmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{jIb|Q5KGh? NHjtbJhIem:5dHigbY5pcWKrdHnvckBw\iCHUj3wc5NqfGm4ZTygTGVTOi2yb4PpeIl3\SCqdX3hckBOTEFvTVKtN|YyKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDXV3QuOSCjc4PhfS=> MkD4NlQ2PTZ3MES=
human AU565 cells M{\WbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWK0PEBp MkTjS5Jwf3SqIHnubIljcXSrb36gc4YhTVJvbnXnZZRqfmVuIFjFVlIueG:|aYTpeoUhcHWvYX6gRXU2PjViY3XscJMh[W[2ZYKgOFghcHK|IHL5JHdUXC1zIHHzd4F6 MXSyOFU2PjVyNB?=
human MCF7 cells NX22SlI4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlzZOFghcA>? NEHGPIRVd3SjbDDndo94fGhiaX7obYJqfGmxbjDv[kBGWi2yb4PpeIl3\SxiSFXSNk1v\WejdHn2[UBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDXV3QuOSCjc4PhfS=> MkTONlQ2PTZ3MES=
human MDA-MB-231 cells MYXGeY5kfGmxbjDhd5NigQ>? MlvnNlQhcA>? NEn1fo1KdmS3Y4Tpc44hd2ZicEKxJIV5eHKnc4Ppc44hcW5iaIXtZY4hWFJuIFXSMEBJTVJ{LX7l[4F1cX[nIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XRiMTD0c{AyOCC3TTDh[pRmeiB{NDDodpMh[nlid3XzeIVzdiCkbH;0JIFv[Wy7c3nz NGrkSnEzPDV3NkWwOC=>
human LS180 cells M{TLb2Z2dmO2aX;uJIF{e2G7 M1TURlIxKM7:TR?= M1PpVmlvcGmkaYTpc44hd2Zic4Xyeol3cW5iZYjwdoV{e2mxbjDpckBx[XKnboSgbJVu[W5iTGOxPFAh[2WubIOgZZQhOjBidV2gZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>? NFn3NXoyPzR5Mkm2Ni=>
human K562 cells Mn35SpVv[3Srb36gZZN{[Xl? MVy0PEBp Mny4TY5pcWKrdHnvckBw\iCJR2Thd4UyKGmwIHj1cYFvKEt3NkKgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKFKjcEHhJJBzd3SnaX6g[4Vz[W67bHfldoFvgWyjdHnvckBi\nSncjC0PEBpenNiYomgW4V{fGW{bjDicI91fGmwZx?= M2LHXFIxQDN{M{K2

... Click to View More Cell Line Experimental Data

Protocol

Solubility (25°C)

In vitro DMSO 8 mg/mL (19.77 mM)
Ethanol 6 mg/mL (14.83 mM)
Water Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 404.54
Formula

C24H36O5

CAS No. 75330-75-5
Storage powder
Synonyms MK-803

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02964884 Not yet recruiting Neurofibromatosis Type 1|Learning Disability Vanderbilt University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) November 2016 Phase 2
NCT02680379 Recruiting Fragile X Syndrome Université de Sherbrooke|FRAXA Research Foundation March 2016 Phase 2
NCT02642653 Recruiting Fragile X Syndrome|Genetic Diseases Randi J. Hagerman, MD|University of California, Davis January 2016 Phase 4
NCT02998151 Enrolling by invitation Fragile X Syndrome Childrens Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) January 2016 Phase 2
NCT02603770 Completed Lipid Metabolism Disorder Luye Pharma Group Ltd. November 2015 Phase 1
NCT02563860 Completed Rett Syndrome Montefiore Medical Center|Rett Syndrome Research Trust July 2015 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HMG-CoA Reductase Signaling Pathway Map

Tags: buy Lovastatin | Lovastatin supplier | purchase Lovastatin | Lovastatin cost | Lovastatin manufacturer | order Lovastatin | Lovastatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID